Article info
Original research
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study
- Correspondence to Professor Sandro Pignata, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli 80131, Italy; s.pignata{at}istitutotumori.na.it
Citation
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study
Publication history
- Received February 1, 2021
- Revision received March 30, 2021
- Accepted March 31, 2021
- First published April 30, 2021.
Online issue publication
June 07, 2021
Article Versions
- Previous version (30 April 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.